by Richard Daverman, PhD
May 18, 2013 -- RuiYi Inc., a San Diego-Shanghai biotech, signed an exclusive license with Genor BioPharma of Shanghai to develop RuiYi’s lead molecule in China; RuiYi also enlisted CMC Biologics to develop a cell line for RYI-008; Vectura, a UK maker of inhaled therapies, established a China respiratory JV with two partners: Tianjin KingYork and Zendex Bio Strategy; SciClone Pharma in-licensed China rights to a heart failure drug from Zensun (Shanghai) Science & Technology; WuXi PharmaTech released positive financial results and candidly discussed the performance of its business units; Amgen, which has not had a major presence in China, is now making good on its promise to use partnerships to establish itself; and BioDuro opened a new CRO laboratory in Shanghai, complementing its existing facility in Beijing. More details…..
Stock Symbols: (LSE: VEC) (NSDQ: SCLN) (NYSE: WX) (NSDQ: AMGN)
